A broken record is right. I previously expressed my displeasure in this regard.
But, during Ken's absence, I was really disappointed with the quality of our corporate communications. This was especially true because Durrant is totally focused on larger issues, such as regulatory authorization/approval, and commencing commercialization. That is how it should be, at this point.
However, shareholder communications is still important, and I'm glad to see consistent messaging, such as Ken provides, even if there are elements of that communication that are redundant, or that I respectfully disagree with.
Three more months will mark the 5th anniversary of my being a HGEN shareholder. So I am likely more tired of waiting than many of you. If any of the various 'accelerated reviews, etc.' we have had over the years meant anything, we could have (and should have) had authorization in March, of 2021.
I don't think Pantginis will be correct regarding his estimate of a 1,455% gain. That's why I started this thread on the topic of sotrovimab. It gives a glimpse into our potential, which could far exceed what Pantginis is projecting.
News 
Market Data 
Discover 
